These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 20663996)

  • 1. Anticoagulation with argatroban for elective percutaneous coronary intervention: population pharmacokinetics and pharmacokinetic-pharmacodynamic relationship of coagulation parameters.
    Akimoto K; Klinkhardt U; Zeiher A; Niethammer M; Harder S
    J Clin Pharmacol; 2011 Jun; 51(6):805-18. PubMed ID: 20663996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Argatroban for elective percutaneous coronary intervention: the ARG-E04 multi-center study.
    Rössig L; Genth-Zotz S; Rau M; Heyndrickx GR; Schneider T; Gulba DC; Desaga M; Buerke M; Harder S; Zeiher AM;
    Int J Cardiol; 2011 Apr; 148(2):214-9. PubMed ID: 20226548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of argatroban in combination with a platelet glycoprotein IIB/IIIA receptor antagonist in patients undergoing percutaneous coronary intervention.
    Cox DS; Kleiman NS; Boyle DA; Aluri J; Parchman LG; Holdbrook F; Fossler MJ
    J Clin Pharmacol; 2004 Sep; 44(9):981-90. PubMed ID: 15317826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Experimental and clinical results with the thrombin inhibitor Argatroban].
    Breddin HK
    Hamostaseologie; 2002 Aug; 22(3):55-9. PubMed ID: 12215762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban.
    Guy S; Kitchen S; Maclean R; Van Veen JJ
    Int J Lab Hematol; 2015 Dec; 37(6):834-43. PubMed ID: 26305560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples.
    Lind SE; Boyle ME; Fisher S; Ishimoto J; Trujillo TC; Kiser TH
    Am J Clin Pathol; 2014 May; 141(5):665-74. PubMed ID: 24713737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic evaluation of argatroban for the treatment of acute coronary syndrome.
    Cruz-González I; López-Jiménez R; Perez-Rivera A; Yan BP
    Expert Opin Drug Metab Toxicol; 2012 Nov; 8(11):1483-93. PubMed ID: 22970706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticoagulant activity and pharmacokinetic properties of a sub-cutaneously administered mixed micellar formulation of argatroban in experimental animals.
    Berry CN; Lunven C; Lecoffre C; Lainée P; O'Connor SE; André F; Roger B; Garrigou-Gadenne D; Rouchouse A; Roome NO; Vivan N
    Thromb Haemost; 2000 Aug; 84(2):278-85. PubMed ID: 10959701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Argatroban pharmacokinetics and pharmacodynamics in critically ill cardiac surgical patients with suspected heparin-induced thrombocytopenia.
    Keyl C; Zimmer E; Bek MJ; Wiessner M; Trenk D
    Thromb Haemost; 2016 Jun; 115(6):1081-9. PubMed ID: 26792118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anticoagulant efficacy and safety of argatroban for patients undergoing elective percutaneous coronary intervention].
    Tian F; Yu H; Chen YD; Liu HB; Guo J; Sun ZJ; Jin QH; Yan F; Ma YL; Gu XF
    Zhonghua Xin Xue Guan Bing Za Zhi; 2013 Jun; 41(6):480-3. PubMed ID: 24113039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects.
    Swan SK; St Peter JV; Lambrecht LJ; Hursting MJ
    Pharmacotherapy; 2000 Jul; 20(7):756-70. PubMed ID: 10907966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombotic actions of the thrombin inhibitor, argatroban, in a canine model of coronary cyclic flow: comparison with heparin.
    Duval N; Lunven C; O'Brien DP; Grosset A; O'Connor SE; Berry CN
    Br J Pharmacol; 1996 Jun; 118(3):727-33. PubMed ID: 8762100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring of argatroban and lepirudin anticoagulation in critically ill patients by conventional laboratory parameters and rotational thromboelastometry - a prospectively controlled randomized double-blind clinical trial.
    Beiderlinden M; Werner P; Bahlmann A; Kemper J; Brezina T; Schäfer M; Görlinger K; Seidel H; Kienbaum P; Treschan TA
    BMC Anesthesiol; 2018 Feb; 18(1):18. PubMed ID: 29426286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A synopsis of the clinical uses of argatroban.
    Moledina M; Chakir M; Gandhi PJ
    J Thromb Thrombolysis; 2001 Oct; 12(2):141-9. PubMed ID: 11729365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coagulation laboratory testing in patients treated with argatroban.
    Walenga JM; Fasanella AR; Iqbal O; Hoppensteadt DA; Ahmad S; Wallis DE; Bakhos M
    Semin Thromb Hemost; 1999; 25 Suppl 1():61-6. PubMed ID: 10357154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris.
    Gold HK; Torres FW; Garabedian HD; Werner W; Jang IK; Khan A; Hagstrom JN; Yasuda T; Leinbach RC; Newell JB
    J Am Coll Cardiol; 1993 Apr; 21(5):1039-47. PubMed ID: 8459055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction.
    Swan SK; Hursting MJ
    Pharmacotherapy; 2000 Mar; 20(3):318-29. PubMed ID: 10730687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The direct thrombin inhibitor argatroban effectively prevents cardiac catheter thrombosis in vitro.
    Raaz U; Kaeberich A; Maegdefessel L; Buerke M; Busshardt M; Schubert S; Russ M; Plehn A; Ebelt H; Werdan K; Schlitt A
    Thromb Haemost; 2010 Apr; 103(4):808-14. PubMed ID: 20174756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined administration of aspirin and a specific thrombin inhibitor in man.
    Clarke RJ; Mayo G; FitzGerald GA; Fitzgerald DJ
    Circulation; 1991 May; 83(5):1510-8. PubMed ID: 2022012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time.
    Harder S; Graff J; Klinkhardt U; von Hentig N; Walenga JM; Watanabe H; Osakabe M; Breddin HK
    Thromb Haemost; 2004 Jun; 91(6):1137-45. PubMed ID: 15175800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.